About: Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
Creator	Bach, Horacio Wooding, Denise
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: There is currently no treatment known to alter the course of COVID-19. Convalescent plasma has been used to treat a number of infections during pandemics, including SARS-CoV, MERS-CoV, and now COVID-19. OBJECTIVES: To summarize the existing literature and registered clinical trials on the efficacy and safety of convalescent plasma for treating coronaviruses, and discuss issues of feasibility, and donor and patient selection. SOURCES: A review of articles published in PubMed was performed on July 13, 2020, to summarize the currently available evidence in human studies for convalescent plasma as a treatment for coronaviruses. The World Health Organization International Clinical Trials Registry and clinicaltrials.gov were searched to summarize the currently registered randomized clinical trials for convalescent plasma in COVID-19. CONTENT: There were sixteen COVID-19, four MERS-CoV, and five SARS-CoV reports describing convalescent plasma use in humans. There were two randomized control trials, both of which were for COVID-19 and were terminated early. Most COVID-19 reports described a potential benefit of convalescent plasma on clinical outcomes in severe or critically ill patients with few immediate adverse events. However, there were a number of limitations, including the concurrent use of antivirals, steroids, and other treatments, small sample sizes, lack of randomization or control groups, and short follow-up time. Data from SARS-CoV and COVID-19 suggest that earlier administration likely yields better outcomes. The ideal candidates for recipients and donors are not known. Still, experience with prior coronaviruses tells us that antibodies in convalescent patients are probably short-lived. Patients who had more severe disease and who are earlier in their course of recovery may be more likely to have adequate titres. Finally, a number of practical challenges were identified. IMPLICATIONS: There is currently no effective treatment for COVID-19, and preliminary trials for convalescent plasma suggest there may be some benefits. However, research to date is at high risk of bias, and randomized control trials are desperately needed to determine the efficacy and safety of this therapeutic option.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1016/j.cmi.2020.08.005
bibo:pmid	32791241
has license	no-cc
sha1sum (hex)	2cc7ef79cdeb7b745f9a061b67344a455141b5bd
schema:url	https://doi.org/10.1016/j.cmi.2020.08.005
resource representing a document's title	Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
has PubMed Central identifier	PMC7417293
has PubMed identifier	32791241
schema:publication	Clin Microbiol Infect
resource representing a document's body	covid:2cc7ef79cdeb7b745f9a061b67344a455141b5bd#body_text
is schema:about of	named entity 'Most' named entity 'convalescent' named entity 'summarize' named entity 'convalescent' named entity 'patient' named entity 'prior' named entity 'steroids' named entity 'convalescent' named entity 'performed' named entity 'Patients' named entity 'COVID' named entity 'coronavirus' named entity 'outbreaks' named entity 'Treatment' named entity 'convalescent' named entity 'PATIENTS' named entity 'TREAT' named entity 'ALTER' named entity 'DONORS' named entity 'TREATED WITH' named entity 'HAVE' named entity 'severe' named entity 'concurrent' named entity 'plasma' named entity 'plasma' named entity 'efficacy' named entity 'experience' named entity 'severe acute respiratory syndrome coronavirus' named entity 'Still' named entity 'selection' named entity 'summarize' named entity 'candidates' named entity 'There' named entity 'However' named entity 'donors' named entity 'MERS-CoV' named entity 'sample sizes' named entity 'plasma' named entity 'The' named entity 'Treatment' named entity 'plasma' named entity 'steroids' named entity 'COVID' named entity 'coronaviruses' named entity 'clinical outcomes' named entity 'SARS-CoV' named entity 'adverse events' named entity 'convalescent plasma' named entity 'Convalescent plasma' named entity 'PubMed' named entity 'COVID-19' named entity 'clinical trials' named entity 'convalescent plasma' named entity 'coronavirus' named entity 'convalescent plasma' named entity 'H1N1' named entity 'convalescent plasma' named entity 'COVID-19' named entity 'COVID' named entity 'clinicaltrials.gov' named entity 'serum' named entity 'convalescent plasma' named entity 'observational studies' named entity 'SARS-CoV' named entity 'convalescent plasma' named entity 'COVID' named entity 'significant effect' named entity 'measles' named entity 'meta-analyses' named entity 'coronavirus' named entity 'serum sickness' named entity 'convalescent plasma' named entity 'blood product' named entity 'randomized control trials' named entity 'COVID' named entity 'convalescent plasma' named entity 'convalescent plasma' named entity 'blood-borne pathogens' named entity 'pathogen' named entity 'coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software